DeCure for Arrhythmogenic right ventricular dysplasia 5
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for arrhythmogenic right ventricular dysplasia 5 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArrhythmogenic right ventricular dysplasia 5 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arrhythmogenic right ventricular dysplasia 5 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Arrhythmogenic right ventricular dysplasia is a cardiomyopathy characterised by a normal or mild increase in heart weight with right-sided heart dilatation, where a proportion of the right ventricular muscle is replaced by fat and fibrous tissue. Clinically it causes episodes of ventricular tachycardia, global dyskinesia of the right ventricle, and may lead to ventricular fibrillation and sudden death, especially in young persons during strenuous exercise or severe emotional outburst. The aetiology is unknown, though familial clustering has been noted. The condition is described as easily overlooked and underdiagnosed.
A 1988 case report illustrates that once suspected, the condition may be diagnosed non-invasively. A 1997 series of three cases of sudden death highlights the range of clinical presentations and histological features seen. A 2003 report describes a 42-year-old woman resuscitated from ventricular fibrillation who had a prior syncope and a nephew who died of sudden cardiac death at age 25. Her ECG showed right precordial T wave inversion; echocardiography and angiography revealed inferior wall akinesia of the right ventricle with normal left ventricular function. Endomyocardial biopsy showed focal fibrous infiltration. Magnetic resonance imaging confirmed inferior wall abnormalities without typical fatty infiltration. Ventricular fibrillation could not be reproduced by programmed stimulation. A cardioverter defibrillator was implanted; within six months the device memory showed no evidence of ventricular fibrillation.
A 2015 lecture reviewed the history, mechanisms, and pathogenesis of arrhythmogenic right ventricular dysplasia, focusing on electrophysiological changes and how this knowledge has modified clinical care. No drug treatment is mentioned in any of these abstracts. The abstracts provide no data on survival rates, response rates, or sample sizes beyond individual case reports. What remains missing is any controlled trial evidence, any pharmacological intervention tested, and any systematic patient stratification that might guide treatment beyond implantable defibrillators.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Medicine Science and the Law · 1997 · 5 citations
4. Arrhythmogenic Right Ventricular Dysplasia (ARVD): An Overlooked and Underdiagnosed Condition?
AbstractWe present three cases of arrhythmogenic right ventricular dysplasia causing or contributing to sudden death. These cases serve to highlight the range of clinical presentations and histological features seen in this rare and poorly understood condition. Arrhythmogenic right ventricular dysplasia (ARVD) is a cardiomyopathy characterized by a normal or mild increase in heart weight with right-sided heart dilatation. Typically a proportion of the right ventricular muscle is replaced by fat and fibrous tissue. Clinically, the condition is characterized by episodes of ventricular tachycardia and global dyskinesia of the right ventricle. It may cause ventricular fibrillation and sudden death, especially in young persons engaged in strenuous exercise or who experience severe emotional outburst. The aetiology of the condition is unknown, although it has been noted to show familial clustering in some cases.
Non‐invasive Recognition of Arrhythmogenic Right Ventricular Dysplasia
AbstractArrhythmogenic right ventricular dysplasia causes ventricular arrhythmias and sometimes heart failure. The condition is easily overlooked, but once suspected, it may be diagnosed non-invasively. This is illustrated by the case reported. The clinical features of this syndrome are discussed, with special emphasis on the non-invasive findings.
Newer Diagnostic and Treatment Options for Patients With ARVC
AbstractThe Intercontinental Lecture, presented by Dr Melvin M. Scheinman, discusses arrhythmogenic right ventricular dysplasia (ARVC). The presenter reviews the history, mechanisms, and pathogenesis of ARVC, with a focus on electrophysiological changes, and then discusses how this new knowledge has modified the clinical approach to the care of this disease.
DMW - Deutsche Medizinische Wochenschrift · 2003 · 0 citations
Arrhythmogene rechtsventrikuläre Dysplasie als Ursache eines überlebten plötzlichen Herztodes
AbstractHISTORY: A 42 year old woman was resuscitated from ventricular fibrillation. 5 months previously she had a syncope. Her nephew had died of sudden cardiac death at the age of 25 years. INVESTIGATIONS: There was no evidence for ST segment elevation, myocardial infarction or pulmonary embolism. The ECG showed right precordial T wave inversion. Coronary artery disease was excluded angiographically. Echocardiography and angiography revealed inferior wall akinesia of the right ventricle with normal left ventricular function and chamber size. Ventricular fibrillation could not be reproduced by programmed stimulation of the right ventricle during an electrophysiologic study. Results of endomyocardial biopsy of the right ventricle showed a focal fibrous infiltration of the myocardium. Magnetic resonance imaging confirmed inferior wall abnormalities of the right ventricle without typical fatty infiltration in the right ventricular myocardium. CLINICAL COURSE: The patient recovered rapidly without neurologic deficits. Arrhythmogenic right ventricular dysplasia was suspected, and a cardioverter defibrillator (ICD) was implanted. Within 6 months after implantation the ICD memory showed no evidence of ventricular fibrillation. CONCLUSION: Arrhythmogenic right ventricular dysplasia is an important cause of ventricular fibrillation with a potential risk of sudden cardiac death in young persons. Concealed arrhythmogenesis as an early manifestation of right ventricular dysplasia is difficult to detect.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
